Oral Prostaglandin E1 in Combination with Sodium Bicarbonate and Normal Saline in the Prevention of Contrast-Induced Nephropathy: A Pilot Study

 

 Buy Article Permissions and Reprints

ABSTRACT

The purpose of this study was to evaluate the use of prostaglandin E1 (PGE1) as a renal protective medication for patients exposed to contrast agents, as well as to demonstrate the safety, efficacy, and low side-effect profile of PGE1. A prospective, randomized, double-blind study was designed to compare combination of intravenous sodium bicarbonate, normal saline, and oral PGE1 200 μg versus the combination and placebo for renal protection from contrast agents. All patients receiving nonionic contrast during their interventional procedure were eligible for enrollment. Creatinine levels were recorded before and after the administration of contrast and renal protective medications. Contrast-induced nephrotoxicity (CIN) was defined as an increase of 0.5 mg/dL or greater in creatinine level, or an increase of 25% or more above baseline. Age, gender, total amount of contrast used, and incidence of renal failure requiring dialysis were recorded. We conducted the study on 41 patients. Of these, 20 patients received PGE1 and 21 received the placebo. The study group comprised 29 males and 12 females. Diabetes mellitus occurred in 41.5% of the cases (including 40% of PGE1 and 43% of placebo patients). Average contrast use was 77.2 mL (range, 15 to 200 mL). Mean age of the groups was 67.2 years. Average baseline creatinine level was 1.17. The differences between the groups were not statistically significant. CIN by definition occurred in one patient, who received the placebo. Incidence of new onset renal failure requiring dialysis was zero. Postcontrast change in creatinine level for the study was 0.11. There was a change in the creatinine level of 0.161 in the PGE1 group and 0.061 in the placebo group; an improvement of 0.10. PGE1 was not effective in significantly altering postcreatinine levels (p = 0.176). None of the patients enrolled in the study suffered any side effects from taking the PGE1 tablet. Although preliminary, this study shows that the addition of PGE1 for the prevention of CIN is well-tolerated by patients and is a safe modality. Additional studies are required to evaluate efficacy.

REFERENCES

• 1 Lautin E M, Freeman N J, Schoenfeld A H et al.. Radiocontrast-associated renal dysfunction: a comparison of lower-osmolality and conventional high-osmolality contrast media.  AJR Am J Roentgenol. 1991;  157 (1) 59-65
  PubMedGoogle Scholar
• 2 Briguori C, Tavano D, Colombo A. Contrast agent-associated nephrotoxicity.  Prog Cardiovasc Dis. 2003;  45 (6) 493-503
  CrossrefPubMedGoogle Scholar
• 3 Levy E M, Viscoli C M, Horwitz R I. The effect of acute renal failure on mortality. A cohort analysis.  JAMA. 1996;  275 (19) 1489-1494
  CrossrefPubMedGoogle Scholar
• 4 Meschi M, Detrenis S, Musini S, Strada E, Savazzi G. Facts and fallacies concerning the prevention of contrast medium-induced nephropathy.  Crit Care Med. 2006;  34 (8) 2060-2068
  CrossrefPubMedGoogle Scholar
• 5 McCullough P A, Wolyn R, Rocher L L, Levin R N, O'Neill W W. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality.  Am J Med. 1997;  103 (5) 368-375
  CrossrefPubMedGoogle Scholar
• 6 Bordet R, Gautier S, Le Louet H, Dupuis B, Caron J. Analysis of the direct cost of adverse drug reactions in hospitalised patients.  Eur J Clin Pharmacol. 2001;  56 (12) 935-941
  CrossrefPubMedGoogle Scholar
• 7 Merten G J, Burgess W P, Gray L V et al.. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial.  JAMA. 2004;  291 (19) 2328-2334
  CrossrefPubMedGoogle Scholar
• 8 Hayashida M, Hanaoka K, Shimada Y, Namiki A, Amaha K. [The effect of low-rose prostaglandin E1 on circulation, respiration and body temperature during surgical anesthesia].  Masui. 1997;  46 (3) 363-372
  PubMedGoogle Scholar
• 9 Ito H, Mitsuhashi S I, Kitamura Y. The response of the renal vasculature to prostaglandin E in man.  Invest Urol. 1976;  13 (4) 295-297
  PubMedGoogle Scholar
• 10 Koch J A, Plum J, Grabensee B, Mödder U. Prostaglandin E1: a new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media? PGE1 Study Group.  Nephrol Dial Transplant. 2000;  15 (1) 43-49
  PubMedGoogle Scholar
• 11 Paller M S, Manivel J C. Prostaglandins protect kidneys against ischemic and toxic injury by a cellular effect.  Kidney Int. 1992;  42 (6) 1345-1354
  CrossrefPubMedGoogle Scholar
• 12 Paller M S. Effects of the prostaglandin E1 analog misoprostol on cyclosporine nephrotoxicity.  Transplantation. 1988;  45 (6) 1126-1131
  CrossrefPubMedGoogle Scholar
• 13 Shield M J. Anti-inflammatory drugs and their effects on cartilage synthesis and renal function.  Eur J Rheumatol Inflamm. 1993;  13 (1) 7-16
  PubMedGoogle Scholar
• 14 Tabo E, Yorozuya T, Shimizu I, Adachi N, Nagaro T, Arai T. [Effects of intravenous nicardipine, prostaglandin E1, nitroglycerin, sodium nitroprusside, and epidural lidocaine on hepatic and renal blood flow during hypotensive anesthesia].  Masui. 2000;  49 (12) 1333-1338
  PubMedGoogle Scholar
• 15 Vargas A V, Krishnamurthi V, Masih R, Robinson A V, Schulak J A. Prostaglandin E1 attenuation of ischemic renal reperfusion injury in the rat.  J Am Coll Surg. 1995;  180 (6) 713-717
  PubMedGoogle Scholar
• 16 Wutte M, Hülsmann M, Berger R et al.. [Improved kidney function with intravenous prostaglandin E1 in patients with terminal heart failure].  Wien Klin Wochenschr. 1998;  110 (13-14) 473-478
  PubMedGoogle Scholar
• 17 Sketch Jr M H, Whelton A, Schollmayer E Prostaglandin E1 Study Group et al.. Prevention of contrast media-induced renal dysfunction with prostaglandin E1: a randomized, double-blind, placebo-controlled study.  Am J Ther. 2001;  8 (3) 155-162
  CrossrefPubMedGoogle Scholar

Randall W. FranzM.D. F.A.C.S. F.I.C.A. R.V.T. 

285 East State Street

Suite 260, Columbus, OH 43215

Email: rfranz2@ohiohealth.com